Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Aptevo Therapeutics, a clinical-stage biotechnology company announced a new solid tumor strategy designed to fight cancer on multiple fronts. The company filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to strengthen Aptevo’s oncology pipeline, expand partnering opportunities and support multiple therapeutic approaches from a single platform-derived innovation.